Thailand Cannabis Law

Thailand made international headlines in 2022 by removing cannabis from its narcotics list, effectively decriminalizing the plant and triggering a rapid commercialization of the cannabis and hemp market. Thousands of dispensaries opened across Bangkok and tourist areas. However, the regulatory framework has been in flux — the government has signaled intent to re-restrict adult-use consumption to medical and scientific purposes only, creating significant regulatory uncertainty for commercial operators.

Thailand remains strategically significant as the first Southeast Asian nation to substantially liberalize cannabis regulation, and as a major tourism destination with proximity to other Asian markets. The Thai FDA (TFDA) administers licensing for medical cannabis products under the Cannabis and Hemp Act. Thailand's herbal medicine framework creates unique pathways for cannabis product commercialization.

Bob Hoban has advised US operators and international investors on Thailand market entry, TFDA licensing requirements, and compliance strategy under Thailand's evolving regulatory regime. Key advisory areas include medical cannabis product licensing, the interface between Thai cannabis law and ASEAN treaty obligations, investment structuring for Thai joint ventures, and the regulatory trajectory toward a more restricted framework.